Aetion is a health analysis company that provides services to entities in the entire life sciences field. get Replica Analytics, a company that uses artificial intelligence to generate data.
New York-based Aetion provides insights based on real-world evidence. Its Aetion Evidence Platform analyzes data from the real world to evaluate the safety, effectiveness and value of drugs. Drug and medical device developers use these insights to guide the development and commercialization of their products. For payers, analysis helps them make reimbursement decisions. However, due to privacy issues, there is a large amount of data that cannot be analyzed. This is where copy analysis can help Aetion.
Copy analysis is generated using AI Synthetic data-Not data from real-world events, but created by sampling real-world data or running simulations. Not just masking or anonymization technology, Synthetic data is new data that retains the privacy and integrity of the original source dataIn a prepared statement, Khaled El Emam, Co-founder and CEO of Replica, stated that privacy rules make most of the world’s health data inaccessible. The technology of the Ottawa, Canada-based company makes data accessible while also protecting privacy, ensuring that customers can comply with regulatory requirements and privacy laws.
After the acquisition, El Emam will continue to stay at Replica as Aetion’s senior vice president and general manager of Replica Analytics. The transaction between the two private companies announced on Tuesday did not disclose any financial terms.
Aetion said that with the addition of Replica, customers of the Aetion platform will now have more privacy-protected data options. Replica said its customer base includes undisclosed Fortune 50 companies. Aetion’s customers include payers and pharmaceutical companies. For example, Sanofi uses Aetion’s technology platform Collect real-world evidence about the effectiveness, safety, and value of its drugs.other Users of this technology include the FDA and Institute of Clinical and Economic Review, A drug price monitoring organization.
Image: Peter Howell, Getty Images
